Cardiol Therapeutics faced a challenging session on the TSX, with its stock declining significantly.
In yesterday's trading session, Cardiol Therapeutics Inc Class A (CRDL.TO) saw its stock price drop by 3.78%, closing at CA$1.78. This decline reflects investor concerns amid a lack of recent positive news to bolster confidence in the company's future prospects.
Advertisement
Cardiol Therapeutics Inc Class A
CRDL.TO
CRDL.TO
Cardiol Therapeutics Inc Class A
WealthAwesomeMarket cap
$216.29M
52W high
$3.23
52W low
$1.23
1W change
-7.77%
Beta
0.72
Analyst Price Targets
Based on analyst covering CRDL · as of Oct 12, 2026
Wall Street analysts forecast CRDL stock price to rise 493.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.00
+493.2% Upside
Previously C$6.00 on Sep 17, 2026
Current Price
C$1.18
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on CRDL's historical volatility
30-Day Vol
68.8%
Annualized
90-Day Vol
65.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.13
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.89 | C$1.49 – C$2.39 |
| 60 trading days | C$2.01 | C$1.43 – C$2.80 |
| 90 trading days | C$2.13 | C$1.41 – C$3.21 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should remain cautious, as Cardiol Therapeutics' recent performance suggests potential volatility and uncertainty in the biotech sector.
3.78% Decline in Stock Price
The 3.78% drop in Cardiol Therapeutics' stock price yesterday indicates growing concern among investors regarding the company's near-term performance.
Bull case
Despite recent setbacks, Cardiol Therapeutics has made significant progress in its clinical trials. If the data supports the efficacy of CardiolRx™, these achievements could lead to positive long-term outcomes.
Bear case
The recent decline in the stock price highlights ongoing skepticism among investors. With no new developments to drive the stock higher in the short term, caution remains prevalent.
Market Reaction
Advertisement
The 3.78% drop in Cardiol Therapeutics' stock price can be attributed to a mix of market sentiment and a lack of significant announcements. While the company has previously reached milestones in its clinical trials, investors are waiting for more concrete data before committing further capital.
Future Outlook
Looking ahead, Cardiol Therapeutics could recover if it delivers positive results from its ongoing clinical trials. However, this recent decline serves as a reminder of the inherent risks associated with investing in biotech stocks, where volatility can be pronounced.
Investor Sentiment
The decline in Cardiol Therapeutics' stock price reflects a broader sentiment of caution among investors in the biotech sector. With no recent news to inspire confidence, stakeholders may be hesitant to increase their positions until more favorable developments arise.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
